One recent study found that 6.28% of the world population, corresponding to 462 million individuals globally, are affected by diabetes, putting an especially heavy weight on the use of dipeptidyl peptidase 4 inhibitors (DPP-4) in diabetic patients’ therapy [14]. This evidence concerns the gene DPP4 and diabetes mellitus.